Abbott Q4 organic base business sales +10.1%; FY2025 adj. EPS guidance $5.05-$5.25

ABBOTT LABORATORIES

2024-FY EPS reported $7.64 revenue$41,950,000,000

Q4 reported sales $11.0B (+7.2% YoY); organic base business (ex-COVID) grew 10.1%.
Q4 GAAP diluted EPS $5.27; adjusted diluted EPS $1.34 (core measure).
Full-year 2024 sales $42.0B (+4.6% reported); organic base business +9.6%; adjusted EPS $4.67.
Medical Devices Q4 sales $5.05B (+13.7% reported); Diabetes Care FreeStyle Libre grew 22.7% to $1.86B.
FY2025 guidance: organic sales growth 7.5%-8.5%; adjusted EPS $5.05-$5.25; op. margin 23.5%-24.0%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.